Rep. David Taylor Buys Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares

Key Points

• Representative David Taylor purchased between $1,001 and $15,000 in shares of Vertex Pharmaceuticals (NASDAQ:VRTX) on August 7th, as disclosed in a recent filing.
• Vertex Pharmaceuticals reported $4.52 earnings per share, exceeding analyst estimates, with quarterly revenue of $2.94 billion, reflecting an 11.3% year-over-year increase.
• Institutional investors hold 90.96% of Vertex Pharmaceuticals' stock, indicating significant confidence in the company's financial health and outlook.

Representative David Taylor (R-Ohio) recently bought shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). In a filing disclosed on September 02nd, the Representative disclosed that they had bought between $1,001 and $15,000 in Vertex Pharmaceuticals stock on August 7th. The trade occurred in the Representative's "DAVID TAYLOR TRUST > SCHWAB JOINT BROKERAGE #1 (HOME GROWN)" account.

Representative David Taylor also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of Eli Lilly and Company NYSE: LLY on 8/14/2025.
• Purchased $1,001 - $15,000 in shares of Marathon Petroleum NYSE: MPC on 8/14/2025.
• Purchased $15,001 - $50,000 in shares of Eli Lilly and Company NYSE: LLY on 8/14/2025.
• Purchased $1,001 - $15,000 in shares of Prologis NYSE: PLD on 8/14/2025.
• Purchased $1,001 - $15,000 in shares of Visa NYSE: V on 8/13/2025.
• Purchased $1,001 - $15,000 in shares of Procter & Gamble NYSE: PG on 8/13/2025.
• Sold $1,001 - $15,000 in shares of Installed Building Products NYSE: IBP on 8/13/2025.
• Purchased $1,001 - $15,000 in shares of Salesforce NYSE: CRM on 8/7/2025.
• Purchased $1,001 - $15,000 in shares of Prologis NYSE: PLD on 8/7/2025.
• Purchased $1,001 - $15,000 in shares of Procter & Gamble NYSE: PG on 8/7/2025.

Vertex Pharmaceuticals Price Performance

Shares of VRTX stock traded down $0.81 during midday trading on Friday, reaching $396.12. 1,171,066 shares of the company traded hands, compared to its average volume of 1,677,311. The firm's 50 day simple moving average is $428.49 and its two-hundred day simple moving average is $456.39. Vertex Pharmaceuticals Incorporated has a 1-year low of $362.50 and a 1-year high of $519.88. The firm has a market cap of $101.56 billion, a PE ratio of 28.31 and a beta of 0.44.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last issued its quarterly earnings data on Monday, August 4th. The pharmaceutical company reported $4.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.24 by $0.28. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%.The firm had revenue of $2.94 billion during the quarter, compared to the consensus estimate of $2.90 billion. During the same period in the previous year, the firm posted ($12.83) EPS. The company's quarterly revenue was up 11.3% compared to the same quarter last year. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, research analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently issued reports on the company. Cantor Fitzgerald cut their price objective on Vertex Pharmaceuticals from $535.00 to $485.00 and set an "overweight" rating for the company in a research report on Tuesday, August 5th. Stifel Nicolaus lowered their target price on shares of Vertex Pharmaceuticals from $494.00 to $455.00 and set a "hold" rating for the company in a research note on Tuesday, August 5th. JPMorgan Chase & Co. lifted their target price on shares of Vertex Pharmaceuticals from $515.00 to $517.00 and gave the stock an "overweight" rating in a research note on Monday, July 14th. UBS Group set a $553.00 target price on shares of Vertex Pharmaceuticals and gave the stock a "buy" rating in a research note on Tuesday, August 5th. Finally, Royal Bank Of Canada lowered their target price on shares of Vertex Pharmaceuticals from $430.00 to $405.00 and set a "sector perform" rating for the company in a research note on Tuesday, August 5th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and thirteen have assigned a Hold rating to the company. Based on data from MarketBeat.com, Vertex Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus price target of $497.10.

Institutional Investors Weigh In On Vertex Pharmaceuticals

A number of institutional investors have recently modified their holdings of VRTX. Activest Wealth Management bought a new stake in shares of Vertex Pharmaceuticals during the 1st quarter valued at about $25,000. Clal Insurance Enterprises Holdings Ltd grew its position in Vertex Pharmaceuticals by 450.0% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 55 shares of the pharmaceutical company's stock worth $27,000 after purchasing an additional 45 shares during the last quarter. Access Investment Management LLC bought a new position in Vertex Pharmaceuticals in the 2nd quarter worth about $27,000. Legacy Investment Solutions LLC bought a new position in Vertex Pharmaceuticals in the 2nd quarter worth about $29,000. Finally, Mascagni Wealth Management Inc. acquired a new stake in shares of Vertex Pharmaceuticals in the 4th quarter worth approximately $31,000. Institutional investors own 90.96% of the company's stock.

Insider Buying and Selling at Vertex Pharmaceuticals

In related news, Director Bruce I. Sachs purchased 5,000 shares of Vertex Pharmaceuticals stock in a transaction dated Wednesday, August 6th. The stock was bought at an average cost of $389.68 per share, with a total value of $1,948,400.00. Following the purchase, the director owned 45,000 shares in the company, valued at approximately $17,535,600. The trade was a 12.50% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 0.20% of the company's stock.

About Representative Taylor

David Taylor (Republican Party) is a member of the U.S. House, representing Ohio's 2nd Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Taylor (Republican Party) ran for election to the U.S. House to represent Ohio's 2nd Congressional District. He won in the general election on November 5, 2024. David Taylor graduated from Amelia High School. Taylor earned degrees from Miami University (Ohio) and the University of Dayton School of Law. Taylor's career experience includes working as an attorney and as a businessman at Sardinia Ready Mix, Inc.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.